Scientists at the University of Manchester have taken an important step towards finding a treatment for age-related macular degeneration (AMD), the most common form of adult blindness in the developed world.

Envision will help students who are blind or visually impaired to enter college and workforce with the acquisition of the College Success Program (CSP).

Developing therapies for genetic forms of blindness is extremely challenging, in part because they vary so widely, but scientists from Trinity College Dublin have highlighted a target with great promise for treating a range of these conditions.

Prevent Blindness will be holding its 17th annual Eyes on Capitol Hill advocacy day as a virtual event on March 1-2, 2022.

A new, detailed genetic roadmap of glaucoma—the world's leading cause of irreversible blindness—will help researchers develop new drugs to combat the disease, by identifying potential target areas to stall or reverse vision loss.

Retinal degenerative diseases, caused by progressive degeneration of the light-sensitive photoreceptors in the retina, is one of the major causes of vision loss and blindness, affecting tens of millions of people worldwide.

Lighthouse Guild Technology Center, which provides the latest assistive devices and cutting-edge technology to people who are blind or visually impaired, recently celebrated its grand opening.

For the first time, University of California, Irvine researchers have revealed at a molecular level, key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrumental to vision.

Researchers in the School of Veterinary Medicine and colleagues have developed a gene therapy that restores dim-light vision in dogs with a congenital form of night blindness, offering hope for treating a similar condition in people.